skip to main
|
skip to sidebar
KinasePro
Daily news on kinase inhibitors.
Friday, August 29, 2008
PDB Update 08/29/08
Ceska, T.A.
Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-Dihydro-2H-benzo[1,4]oxazines
Resolution: 2.85 Å
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
Labels
550
(1)
Abbott
(1)
Akt
(1)
Amgen
(1)
Angiokinase
(1)
Astellas
(1)
Aurora2
(1)
Axitinib
(1)
B-Raf
(2)
BMS
(2)
Boehringer Ingelheim
(1)
C-MET
(2)
CAMK2A
(1)
CDK
(1)
CEP-1347
(1)
Cephalon
(2)
CK1e
(1)
Clinical Trial
(10)
Computational
(4)
CP-690
(1)
Dasatinib
(1)
Eberhard-Karls-University Tuebingen
(1)
EGFR
(1)
Genentech
(1)
GSK
(2)
GSK3
(1)
IGF-1R
(1)
IRAK4
(1)
JAK2
(1)
JNK
(1)
Lapatinib
(1)
Lck
(1)
Motesanib
(1)
mTOR
(1)
Nilotinib
(1)
p38
(2)
PDB
(3)
PDK1
(1)
Pfizer
(3)
Phase II
(1)
PI3K
(2)
Pim1
(1)
Piramed
(1)
PKA
(1)
PLK
(1)
Plk1
(1)
Riboxistaurin
(1)
Sorafenib
(1)
Src
(1)
Sunitinib
(1)
Tie1
(1)
TrkA
(1)
UCB
(1)
University of Florida
(1)
University of Kentucky
(1)
University of Pittsburgh
(1)
University of Rhode Island
(1)
Blog Archive
►
2009
(1)
►
07/05 - 07/12
(1)
▼
2008
(32)
►
09/07 - 09/14
(3)
►
08/31 - 09/07
(10)
▼
08/24 - 08/31
(11)
PDB Update 08/29/08
Clinical Trial Results of Nilotinib
Clinical Trial Results of Sunitinib
Clinical Trial Results of Lapatinib
Clinical Trial Results of Ruboxistaurin
Clinical Trial Results of CEP-1347
Clinical Trial Results of Axitinib
Clinical Trial Results of Dasatinib
Clinical Trial Results of Motesanib
Clinical Trial Results of Sorafenib
PDB Update 08/26/08
►
08/17 - 08/24
(8)
On the Market
Dasatinib
Erlotinib
Gefitinib
Imatinib
Lapatinib
Nilotinib
Temsirolimus
No comments:
Post a Comment